Earnings per Share

3 Months Ended

Mar. 31, 2024

In the first quarter of 2024 and 2023, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact.

The following table sets forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share (in thousands, except per share amounts):


	For the Three Months Ended March 31,
		2024		2023
Numerator
Consolidated net (loss)/income		$	(4,273)	$	509,089
Less: Net income attributable to continuing non-controlling interests		1,539		123,257
Less: Net (loss)/income attributable to legacy non-controlling interests		(10,590)		45,077
Net income attributable to Royalty Pharma plc - basic		4,778		340,755
Add: Reallocation of net income attributable to non-controlling interests from the assumed conversion of Class B ordinary shares		1,539		123,257
Net income attributable to Royalty Pharma plc - diluted		$	6,317	$	464,012

Denominator
Weighted average Class A ordinary shares outstanding - basic		448,623		445,612
Add: Dilutive effects as shown separately below
Class B ordinary shares exchangeable for Class A ordinary shares		148,812		161,612
Unvested RSUs		44		27
Weighted average Class A ordinary shares outstanding - diluted		597,479		607,251

Earnings per Class A ordinary share - basic		$	0.01	$	0.76
Earnings per Class A ordinary share - diluted		$	0.01	$	0.76